Form 8-K
8-K — Dermata Therapeutics, Inc.
Accession: 0001493152-26-050964
Filed: 2026-11-10
Period: 2026-11-10
CIK: 0001853816
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-99.1 (ex99-1.htm)
GRAPHIC (ex99-1_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001853816
0001853816
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 10, 2026
DERMATA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
001-40739
86-3218736
(State
or other jurisdiction
(Commission
(IRS
Employer
of
incorporation)
File
Number)
Identification
No.)
3525
Del Mar Heights Rd., #322
San
Diego, CA
92130
(Address
of principal executive offices)
(Zip
Code)
(858)
800-2543
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of exchange on which registered
Common
Stock, par value $0.0001 per share
DRMA
The
Nasdaq Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
2.02. Results of Operation and Financial Condition.
On
November 10, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding
its results of operations for the quarter ended September 30, 2026, and provided a corporate update. A copy of the press release is furnished
under Item 2.02 as Exhibit 99.1.
The
information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed”
for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange
Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange
Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such
filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
99.1
Press Release, dated November 10, 2026, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026”
104
Cover
Page Interactive Data File (embedded within the Inline XBRL document).
-2-
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
DERMATA
THERAPEUTICS, INC.
Dated:
November 10, 2026
By:
/s/
Gerald T. Proehl
Name:
Gerald
T. Proehl
Title:
President,
Chairman and Chief Executive Officer
-3-
EX-99.1
EX-99.1
Filename: ex99-1.htm · Sequence: 2
Exhibit
99.1
Dermata
Therapeutics Provides Corporate Update
and
Reports Financial Results for the Third Quarter 2026
-
Dermata generates product revenue following the launch of its first commercial product,
Tome™
Foundational Treatment, on August 25, 2026 -
-
Tome Skincare ecommerce platform establishes a foundation for product growth through direct-to-consumer sales, subscriptions, and professional
skincare channels -
-
Positive topline results from a cosmetic clinical study in which participants demonstrated improvements across multiple measures of skin
appearance provides clinical support for the commercialization strategy of Tome Foundational Treatment as “Studied Skincare”
-
SAN
DIEGO, CA, November 10, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”),
a science-driven leader in dermatologic solutions focused on the development and commercialization of consumer and professional skincare
products, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2026.
“The
third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company
to a revenue-generating commercial skincare business,” commented Gerry Proehl, Dermata’s Chairman, President, and Chief Executive
Officer. “With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking
an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient,
consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder. We are excited about
the early interest in our Tome Foundational Treatment, including approximately 30% of orders generated via subscriptions. We believe
our subscribers will help establish the foundation for a scalable business with opportunities to expand consumer awareness, develop recurring
revenue through subscriptions, and introduce our products to skincare professionals.”
“Importantly,
our strategy extends beyond the launch of a single product. Recently, we initiated a clinical trial evaluating Tome Clearing Treatment,
our second planned commercial product for the treatment of acne, which we expect to launch in the first half of 2027,” continued
Mr. Proehl.
“Looking
ahead, our priorities are focused on increasing brand awareness of Tome, converting consumer interest into sales, expanding our distribution
opportunities, and building a broader portfolio of products powered by Bioneedle. We believe our combination of clinical expertise, differentiated
skincare technology, and direct-to-consumer commercialization provides an opportunity to build a growing skincare business with multiple
potential revenue streams and create long-term value for our shareholders,” concluded Mr. Proehl.
Recent
Corporate Highlights
● Launched
Tome Foundational Treatment and generated revenue. On August 25, 2026, Dermata officially
launched Tome Foundational Treatment, its first commercial skincare product, through its
direct-to-consumer website. The launch represents a significant milestone in the Company’s
strategic transition to commercial skincare and provides Dermata with its first opportunity
to generate revenue from product sales. Tome Foundational Treatment is a once-weekly skin
renewal treatment powered by the Company’s Bioneedle technology and is designed to
improve the appearance of skin tone, texture, fine lines, and dark spots.
● Announced
positive topline results from cosmetic clinical study of Tome Foundational Treatment.
In October 2026, Dermata announced positive topline results from its completed cosmetic clinical
study evaluating Tome Foundational Treatment in 31 participants over four weeks. The study
demonstrated improvements across multiple investigator-assessed measures of skin appearance,
including fine lines, hyperpigmentation, radiance, and overall appearance. More than 71%
of participants were graded as having overall improvement in skin appearance after just one
treatment. The Company believes these results support Tome’s positioning as “studied
skincare” and provides clinically supported content to enhance consumer education,
strengthen brand credibility, and support future marketing efforts.
● Continued
building brand awareness and market visibility for Tome. Surrounding the Tome Foundational
Treatment commercial launch, Dermata has focused on introducing Tome to consumers through
digital marketing, social media, public relations, and editorial outreach. The Company believes
that building awareness of Tome’s Bioneedle technology and once-weekly application
format will be important in supporting customer acquisition and expanding its presence in
the premium skincare market.
● Advanced
development of second commercial skincare product for acne. In October 2026, Dermata
announced enrollment of the first participant in a clinical trial evaluating Tome Clearing
Treatment, its second planned commercial product. Tome Clearing Treatment combines salicylic
acid, an FDA-recognized over-the-counter acne active ingredient, with the Company’s
Bioneedle technology in a once-weekly treatment regimen for the treatment of acne. The Company
expects to launch Tome Clearing Treatment in the first half of 2027, subject to successful
development and commercialization activities. Dermata believes the addition of a second product
could expand its addressable consumer market, create cross-selling opportunities, and diversify
its commercial revenue base.
Anticipated
Upcoming Milestones
● Drive
commercial growth of Tome Foundational Treatment. The Company plans to continue executing
its direct-to-consumer marketing strategy to increase brand awareness, attract new customers,
and encourage repeat purchases. Dermata intends to leverage clinical study results, consumer
education, and digital marketing to communicate the benefits of its Bioneedle technology
and support future sales growth.
● Expand
Tome’s professional skincare presence. Dermata intends to expand opportunities
to introduce Tome Foundational Treatment to aestheticians, dermatologists, and other skincare
professionals for in-office use and recommendations to their clients and patients. The Company
believes professional adoption could provide an additional revenue opportunity while supporting
broader consumer awareness and credibility of the Tome brand.
● Advance
Tome Clearing Treatment toward commercial launch in the first half of 2027. Dermata plans
to continue its clinical evaluation of Tome Clearing Treatment, with the goal of generating
evidence of its effect on acne to support its planned commercialization. The Company believes
its second product will expand Tome’s portfolio into the large consumer acne market
and support the Company’s strategy of building a multi-product skincare business.
● Continued
optimization of commercial operations and revenue opportunities. As Dermata progresses
through its initial commercialization period, the Company plans to evaluate customer purchasing
patterns, subscription participation, marketing performance, and other commercial metrics
to inform its growth strategy and capital allocation decisions.
Third
Quarter 2026 Financial Results
As
of September 30, 2026, the Company had $5.0 million in cash, cash equivalents and restricted cash, compared to $7.5 million as of December
31, 2025. The $2.5 million decrease in cash, cash equivalents and restricted cash for the nine months ended September 30, 2026, resulted
from $7.6 million of cash used in operations, and $0.2 million of cash used in investing activities, offset by financing activities of
approximately $2.0 million in net proceeds from the Company’s ATM and $3.2 million of net proceeds related to its August 2026 financing
transaction. The Company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.
Net
sales and cost of sales were $74,000 and $34,000, respectively, for the quarter ended September 30, 2026, related to sales of the Company’s
first commercial product, Tome Foundational Treatment. Gross profit was $40,000 for the quarter ended September 30, 2026, reflecting
an approximate 54% profit margin.
Research
and development expenses were $0.1 million for the quarter ended September 30, 2026, compared to $0.5 million for the quarter ended September
30, 2025. The $0.4 million decrease in research and development expenses resulted primarily from reallocation of employee duties to focus
on the commercial launch of the Company’s first product, Tome Foundational Treatment.
Selling,
general and administrative expenses were $2.8 million for the quarter ended September 30, 2026, compared to $1.3 million for the quarter
ended September 30, 2025. The increase in selling, general and administrative expenses of $1.5 million was primarily attributable to
the Company’s decision to prioritize the commercial launch of its first product, resulting in significant commercialization activities
during the quarter ended September 30, 2026. This resulted in an increase of $0.2 million of marketing and other commercialization expenses
and an increase of $0.5 million of compensation expense primarily due to a reallocation of employee duties from research and development
to selling, general and administrative expense, as a result of the shift in business focus towards commercialization. In addition, legal
fees increased by $0.8 million during the quarter ended September 30, 2026, due to ongoing litigation and new trademarks.
About
Tome Skincare
Tome
is Dermata’s skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal
meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in
science and history. Tome consists of skincare products utilizing a wild harvested freshwater sponge that has evolved over centuries
for consumers compelled by history and science to find potent natural products for their skincare routine. Dermata believes its Tome
skincare line can simplify existing skincare routines with essential ingredients designed to deliver results, without harmful extremes.
Start
your skincare story at Tome.
About
Dermata Therapeutics
Dermata
Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of both direct-to-consumer
and professional skincare solutions. The Company leverages its experience in clinical dermatology and its Bioneedle technology to develop
differentiated skincare products designed to address a variety of consumer skincare needs. Dermata’s first commercial product,
Tome Foundational Treatment, is now available at Tome, with additional innovations planned to follow. Dermata is headquartered
in San Diego, California.
For
more information, please visit Dermata.
Forward-Looking
Statements
Statements
in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s
current beliefs and expectations, and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to
prioritize direct-to-consumer (DTC) and over-the-counter (OTC) skincare products; the anticipated benefits of Dermata’s strategic
shift to prioritize DTC and OTC skincare products, including acceleration of its path to commercialization, and expansion into broader
consumer markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Clearing
Treatment; the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the
Company’s products and their ability to generate revenue for the Company; the Company’s expectations with regard to current
cash, cash equivalents, and restricted cash and the amount of time it will fund operations; and other factors described in the Company’s
filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words
as “may,” “could,” “should,” “would,” “believe,” “anticipate,”
“forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,”
“outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. These
statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of such statements due to various factors, including the risks and
uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata’s
filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation
to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
DERMATA
THERAPEUTICS, INC.
Balance
Sheets
In thousands
USD
September 30,
2026
December 31,
2025
(unaudited)
Assets
Cash and cash equivalents
$ 4,822
$ 7,522
Restricted cash
200
-
Prepaid expenses and other current assets
583
342
Inventories
825
-
Non-current assets
205
-
Total assets
6,635
7,864
Liabilities
Accounts payable
1,620
461
Accrued liabilities
1,110
1,180
Total liabilities
2,730
1,641
Equity
3,905
6,223
Total
liabilities and equity
$ 6,635
$ 7,864
DERMATA
THERAPEUTICS, INC.
Statements
of Operations
(unaudited)
Quarter
Ended
September
30,
Nine
Months Ended
September
30,
In
thousands, except share and per share data
2026
2025
2026
2025
Net sales
$ 74
$ -
$ 74
$ -
Cost of sales
(34 )
-
(34 )
-
Gross profit
40
-
40
-
Operating expenses
Research and development (1)
143
504
739
2,403
Selling, general and administrative
(1)
2,755
1,256
7,099
3,470
Total operating expenses
2,898
1,760
7,838
5,873
Loss from operations
(2,858 )
(1,760 )
(7,798 )
(5,873 )
Interest income
37
69
162
176
Net
loss
$ (2,821 )
$ (1,691 )
$ (7,636 )
$ (5,697 )
Net loss per common
share, basic and diluted
$ (0.55 )
$ (1.65 )
$ (1.76 )
$ (6.64 )
Weighted average common
shares outstanding, basic and diluted
5,119,529
1,026,457
4,338,149
858,015
(1) Includes the following stock-based compensation
expense
Research and development
$ 4
$ 8
$ 22
$ 24
Selling, general and administrative
$ 38
$ 30
$ 105
$ 90
Investor
Contact:
Cliff
Mastricola
Investor
Relations
cmastricola@dermatarx.com
GRAPHIC
GRAPHIC
Filename: ex99-1_001.jpg · Sequence: 3
Binary file (17712 bytes)
Download ex99-1_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Cover
Nov. 10, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Nov. 10, 2026
Entity File Number
001-40739
Entity Registrant Name
DERMATA
THERAPEUTICS, INC.
Entity Central Index Key
0001853816
Entity Tax Identification Number
86-3218736
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
3525
Del Mar Heights Rd.
Entity Address, Address Line Two
#322
Entity Address, City or Town
San
Diego
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
92130
City Area Code
(858)
Local Phone Number
800-2543
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, par value $0.0001 per share
Trading Symbol
DRMA
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
true
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration